

NCIC CLINICAL TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING
AGENDA

ROOM: CHURCHILL A

DELTA CHELSEA, TORONTO, ON

SATURDAY, MAY 2ND, 2009

CHAIRS: DR. G. GOSS & DR. Y. UNG
(8:30 A.M. – 4:15 P.M.)

-
- | | | |
|------------|--|------------------|
| 8:30 A.M. | WELCOME AND ANNOUNCEMENTS | DR. G. GOSS |
| 9:00 A.M. | UPDATE ON NCI INTEGRATED THORACIC MALIGNANCIES STEERING COMMITTEE | |
| 9:05 A.M. | <u>SUBCOMMITTEE REPORTS</u> | |
| | • SMALL CELL | DR. P. ELLIS |
| | • RADIATION | DR. Y. UNG |
| | • MESOTHELIOMA AND THYMOMA | DR. C. LEE |
| | • CORRELATIVE SCIENCES | DR. M. TSAO |
| 9:45 A.M. | COFFEE BREAK (~ 20 MINUTES) | |
| 10:05 A.M. | <u>NON-SMALL CELL LUNG CANCER</u> | |
| | <u>SURGICAL ADJUVANT AND NEOADJUVANT AND LOCALLY ADVANCED TRIALS</u> | |
| BR.16: | RANDOMIZED PLACEBO CONTROLLED TRIAL OF ADJUVANT SELENIUM IN COMPLETELY RESECTED STAGE I NSCLC (ECOG) | DR. T. WADDELL |
| BR.19: | RANDOMIZED TRIAL OF ADJUVANT GEFITINIB VERSUS PLACEBO AFTER COMPLETE RESECTION OF STAGE IB, II IIIA NSCLC | DR. G. GOSS |
| BRC.2: | (ECOG 1505) RANDOMIZED TRIAL OF CHEMOTHERAPY +/- BEVACIZUMAB IN COMPLETELY RESECTED STAGE IB-III A NSCLC | DR. C. BUTTS |
| BRC.2: | (ECOG 1505) RANDOMIZED TRIAL OF CHEMOTHERAPY +/- BEVACIZUMAB IN COMPLETELY RESECTED STAGE IB-III A NSCLC
<i>ECONOMIC ANALYSIS</i> | DR. N. LEIGHL |
| BRC.5: | (CALGB 140503) A PHASE III RANDOMIZED TRIAL OF LOBECTOMY VERSUS SUB-LOBAR RESECTION FOR SMALL (< 2 CM) PERIPHERAL NSCLC | DR. M. DE PERROT |
| BR.27: | (LUNG-ART) POST-OPERATIVE ADJUVANT RADIATION FOR COMPLETELY RESECTED N2 NSCLC | DR. Y UNG |

CONTINUED ...

- 11:05 A.M. **ADVANCED NSCLC**
- BR.24: RANDOMIZED TRIAL OF PACLITAXEL AND CARBOPLATIN
+/- AZD 2171 IN ADVANCED NON-SCLC DR. G. GOSS
- BRC.4: (N0723) A PHASE III BIOMARKER VALIDATION STUDY OF
SECOND-LINE THERAPY IN PATIENTS WITH ADVANCED
NSCLC RANDOMIZED TO PEMETREXED VERSUS ERLOTINIB DR. G. LIU
- BR.29: A DOUBLE BLIND RANDOMIZED TRIAL OF CEDIRANIB VERUS
PLACEBO IN PATIENTS RECEIVING PACLITAXEL/CARBOPLATIN
CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED OR
METASTATIC NON-SMALL CELL LUNG CANCER DR. S. LAURIE
- 11:30 A.M. **RADIOTHERAPY STUDIES**
- BR.25: HYPOFRACTIONATED RADIOTHERAPY FOR MEDICALLY
INOPERABLE NSCLC DR. P. CHEUNG
- BRC.1: PCI IN NSCLC DR. A. SUN
- RTOG 0212: PCI IN SCLC DR. A. SUN
- 11:50 P.M. **SMALL CELL LUNG CANCER**
- BR.28: (CONVERT) ONCE DAILY VERSUS TWICE DAILY RADIATION
FOR LIMITED SCLC DR. A. BEZJAK
- 12:00 P.M. LUNCH (90 MINUTES)
- 1:30 P.M. **IND STUDIES**
- IND.183: PHASE II TRIAL OF SUTENT IN 2ND-LINE TREATMENT OF
MALIGNANT MESOTHELIOMA DR. S. LAURIE
- IND.190: PHASE I-II TRIAL OF ETOPOSIDE / CISPLATIN + IGFR1
INHIBITOR IN EXTENSIVE STAGE SCLC DR. P. ELLIS
- IND 196: PHASE I/II C-MET INHIBITOR/ERLOTINIB DR. N. LEIGHL / DR. C. HO
- REPORT FROM THE IND COMMITTEE DR. G. GOSS
- 2.30 P.M. COFFEE BREAK (~ 15 MIN)
- 2:45 P.M. **ECONOMIC AND DATA-BASE ANALYSES OF LUNG TRIALS**
- ECONOMIC ANALYSES - ACTIVE AND PLANNED DR. N. LEIGHL
 - DATABASE ANALYSES DR. F. SHEPHERD
- 3:30 P.M. **NEW STUDIES**
- BR.26 DR. P. ELLIS
 - OTHER DR. G. GOSS
- 4:00 P.M. **CONCLUSIONS**